Sotagliflozin Rejected for T1D; Thyroid and COVID; Diabetes Drug Price Cut

(MedPage Today) -- The FDA rejected sotagliflozin (Zynquista) as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and chronic kidney disease, said maker Lexicon Pharmaceuticals. The decision was expected following...